MX2023012536A - Regimen de dosificacion universal de 25-hidroxivitamina d3. - Google Patents
Regimen de dosificacion universal de 25-hidroxivitamina d3.Info
- Publication number
- MX2023012536A MX2023012536A MX2023012536A MX2023012536A MX2023012536A MX 2023012536 A MX2023012536 A MX 2023012536A MX 2023012536 A MX2023012536 A MX 2023012536A MX 2023012536 A MX2023012536 A MX 2023012536A MX 2023012536 A MX2023012536 A MX 2023012536A
- Authority
- MX
- Mexico
- Prior art keywords
- dosage regime
- hydroxy vitamin
- vitamin
- relates
- dosage
- Prior art date
Links
- JWUBBDSIWDLEOM-UHFFFAOYSA-N 25-Hydroxycholecalciferol Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CCC1=C JWUBBDSIWDLEOM-UHFFFAOYSA-N 0.000 title abstract 2
- JWUBBDSIWDLEOM-DCHLRESJSA-N 25-Hydroxyvitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C/C=C1\C[C@@H](O)CCC1=C JWUBBDSIWDLEOM-DCHLRESJSA-N 0.000 title abstract 2
- JWUBBDSIWDLEOM-NQZHSCJISA-N 25-hydroxy-3 epi cholecalciferol Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=CC=C1C[C@H](O)CCC1=C JWUBBDSIWDLEOM-NQZHSCJISA-N 0.000 title abstract 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- JWUBBDSIWDLEOM-XHQRYOPUSA-N (3e)-3-[(2e)-2-[1-(6-hydroxy-6-methylheptan-2-yl)-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol Chemical compound C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2\C1=C\C=C1/CC(O)CCC1=C JWUBBDSIWDLEOM-XHQRYOPUSA-N 0.000 abstract 1
- 235000021318 Calcifediol Nutrition 0.000 abstract 1
- 206010047626 Vitamin D Deficiency Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008203 oral pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se refiere a una composición farmacéutica oral de liberación inmediata para uso en la prevención y/o tratamiento de una enfermedad o afección causada por deficiencia de vitamina D. La invención también se refiere a un método para aumentar y/o mantener los niveles séricos de 25-hidroxivitamina D en un sujeto hasta un valor igual o superior a 20 ng/mL que comprende la administración a dicho sujeto de una composición oral de liberación inmediata. La composición de la invención comprende de 0,050 a 0,175 mg de 25-hidroxivitamina D3 por unidad de dosificación y cada unidad de dosificación es para administración siguiendo un régimen de dosificación de al menos una vez por semana en el que el régimen de dosificación se mantiene durante un período de al menos 1 mes. La invención se refiere además a un método para adaptar el régimen de dosificación.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IB2021/000242 WO2022224001A1 (en) | 2021-04-22 | 2021-04-22 | Universal dosage regime of 25-hydroxy vitamin d3 |
| PCT/EP2021/075467 WO2022223139A1 (en) | 2021-04-22 | 2021-09-16 | Universal dosage regime of 25-hydroxy vitamin d3 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023012536A true MX2023012536A (es) | 2023-12-06 |
Family
ID=75919339
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023012536A MX2023012536A (es) | 2021-04-22 | 2021-09-16 | Regimen de dosificacion universal de 25-hidroxivitamina d3. |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP4326279A1 (es) |
| CL (1) | CL2023003153A1 (es) |
| CO (1) | CO2023015568A2 (es) |
| DO (1) | DOP2023000235A (es) |
| EC (1) | ECSP23085567A (es) |
| MX (1) | MX2023012536A (es) |
| PE (1) | PE20240014A1 (es) |
| WO (2) | WO2022224001A1 (es) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20100126376A (ko) * | 2008-02-13 | 2010-12-01 | 디에스엠 아이피 어셋츠 비.브이. | 골 무기질 밀도를 개선시키고 골다공증을 치료하기 위한 25-하이드록시-비타민 ｄ3과 비타민 ｄ3의 조합된 용도 |
| US8759328B2 (en) * | 2008-07-24 | 2014-06-24 | Wisconsin Alumni Research Foundation | Once-a-week administration of 25-hydroxy vitamin D3 to sustain elevated steady-state pharmacokinetic blood concentration |
| WO2014179737A2 (en) * | 2013-05-03 | 2014-11-06 | The General Hospital Corporation | Assays and methods of treatment relating to vitamin d insufficiency |
| EP3053598A1 (en) | 2015-02-06 | 2016-08-10 | Faes Farma, S.A. | Calcifediol soft capsules |
| CN108883120A (zh) | 2016-03-28 | 2018-11-23 | 欧普科爱尔兰环球控股有限公司 | 维生素d治疗方法 |
-
2021
- 2021-04-22 WO PCT/IB2021/000242 patent/WO2022224001A1/en not_active Ceased
- 2021-09-16 WO PCT/EP2021/075467 patent/WO2022223139A1/en not_active Ceased
- 2021-09-16 PE PE2023002922A patent/PE20240014A1/es unknown
- 2021-09-16 MX MX2023012536A patent/MX2023012536A/es unknown
- 2021-09-16 EP EP21773837.6A patent/EP4326279A1/en active Pending
-
2023
- 2023-10-20 DO DO2023000235A patent/DOP2023000235A/es unknown
- 2023-10-20 CL CL2023003153A patent/CL2023003153A1/es unknown
- 2023-11-13 EC ECSENADI202385567A patent/ECSP23085567A/es unknown
- 2023-11-17 CO CONC2023/0015568A patent/CO2023015568A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4326279A1 (en) | 2024-02-28 |
| CL2023003153A1 (es) | 2024-05-10 |
| WO2022223139A1 (en) | 2022-10-27 |
| DOP2023000235A (es) | 2023-11-30 |
| PE20240014A1 (es) | 2024-01-04 |
| WO2022224001A1 (en) | 2022-10-27 |
| CO2023015568A2 (es) | 2023-12-11 |
| ECSP23085567A (es) | 2023-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6136859A (en) | Pharmaceutical formulation for treating liver disorders | |
| JP5563296B2 (ja) | 二次性副甲状腺機能亢進症の治療及び予防方法 | |
| IL178745A (en) | Use of 4- (amino) -2 (2, 6-dioxo (3-piperidyl)) -isoindoline -1, 3-discussion of preparation of a medical vaccine for the treatment of myeloma | |
| WO2005065069A3 (en) | Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease | |
| RU2008103617A (ru) | Бисфосфоновые кислоты, предназначенные для лечения и профилактики остеопороза | |
| AU741511B2 (en) | Pharmaceutical composition comprising at least tyrosine and an iron compound fortreating parkinson's disease or depression | |
| CA2735834C (en) | Composition comprising ibuprofen and paracetamol to treat pain caused by osteoarthritis and rheumatoid arthritis | |
| MX2021008208A (es) | Tesofensina para la reduccion del peso corporal para pacientes con sindrome de prader-willi. | |
| MX2023012536A (es) | Regimen de dosificacion universal de 25-hidroxivitamina d3. | |
| JP2025031720A5 (es) | ||
| MX2024015896A (es) | Composicion farmaceutica que comprende un agonista del receptor de adenosina a3 para el tratamiento de la psoriasis | |
| US20070134320A1 (en) | Composition and regimen for the treatment of Herpes Simplex Virus, Herpes Zoster, and Herpes Genitalia epidermal herpetic lesions | |
| JP2021517128A5 (es) | ||
| CA2219354A1 (en) | Prevention of tooth loss by the administration of alendronate or its salts | |
| KR20030019444A (ko) | 안지오텐신 ⅱ 길항물질의 신규한 용도 | |
| JPH04342528A (ja) | アルコール代謝およびアセトアルデヒド代謝促進剤 | |
| ZA202401265B (en) | Progestogen-only oral contraception | |
| CN120919102A (zh) | 蛋氨酸在制备用于改善精神分裂症社交障碍的药物或组合物中的用途 | |
| US11364218B2 (en) | Method of treating or preventing mood disorders, mental disorders, and/or chronic fatigue syndrome | |
| US8586537B2 (en) | Method for treating minor aphthous ulcers | |
| JPH04112823A (ja) | 痴呆治療剤 | |
| Janicak et al. | Verapamil for acute mania: preliminary results from a double-blind, placebo-controlled study | |
| US20220304986A1 (en) | Compositions and methods for treating acquired brain injury and post-traumatic stress disorder | |
| GB2121277A (en) | Preparations for combating colds and flu, containing iron salt and calcium lactate | |
| JP2018508548A (ja) | 膀胱機能を改善する方法 |